|Poll|January 23, 2017

Mini Quiz: Characterizing Sexual Deviation

Key Takeaways

A quiz on significant changes in DSM-5 nomenclature as they relate to sexual disorders.

The DSM originally characterized sexual deviations as:

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Sex and Psychiatry: The Sizzling, Steamy, Neglected Topic

ByFrank A. Clark, MD,Brittany Albright, MD, MPH

June 19th 2025

In Conversation With a Sigourney Award Winner: Gender & Sexuality

ByJack Drescher, MD

April 12th 2023

How A Psychoanalyst Brought His Field’s Thinking about Gender and Sexuality Into the 21st Century

ByJack Drescher, MD

April 5th 2023

Sex, Loneliness, the Super Bowl, and Valentine’s Day

ByH. Steven Moffic, MD

February 14th 2023

Avoid “Shots in the Dark” to Maintain Pristine Professional Boundaries

BySteve Adelman, MD

August 25th 2022

Latest CME

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Mini Quiz: Characterizing Sexual Deviation

Key Takeaways

Newsletter

Related Content

Sex and Psychiatry: The Sizzling, Steamy, Neglected Topic

In Conversation With a Sigourney Award Winner: Gender & Sexuality

How A Psychoanalyst Brought His Field’s Thinking about Gender and Sexuality Into the 21st Century

Sex, Loneliness, the Super Bowl, and Valentine’s Day

Avoid “Shots in the Dark” to Maintain Pristine Professional Boundaries

Latest CME

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Psychedelic PSX-001 for Generalized Anxiety Disorder: A Conversation With Lou Barbato, MD

The Concept of Mental Illness, and Why the DSM Approach Is Wrong

Antidepressants Assessed for Reducing Negative Symptoms of Schizophrenia

Favorable Profile Data On MK-2214 for Treatment of Alzheimer Disease

Okie Tokie Talk: Adolescent Cannabis Use in Oklahoma, the Sooner State